Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6010697

Title:Infusion of neutrophil precursors for treatment of neutropenia
Inventors:Smith, Stephen L.; Arlington Heights, IL, USA
Qiao, Xiaoying; Waukegan, IL, USA
Maciukas, SUSA
n M.; El Cerrito, CA, USA
Loudovaris, Maureen F.; Grayslake, IL, USA
Bender, James G.; Lindenhurst, IL, USA
Van Epps, Dennis E.; Cary, IL, USA
Summary:Described herein are methods of treating a human patient having a reduced neutrophil count by administration of neutrophil precursors in a serum-free and animal protein-free cell suspension. The invention relates to a method of treatment following myeloablative cancer therapy such as high dose chemotherapy. Further disclosed are properties of the cell medium such that it contains at least 25% neutrophil precursors including promyelocytes, myelocytes, and metamyelocytes, and such that the composition is administered to the patient following myeloablative therapy, after which the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils, thereby stimulating the patientís immunological capacity to fight infection. Claims of the invention include a reduction in the neutropenic window that exists between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils.
Abstract:The invention provides a method of treating a patient having a reduced population of neutrophils following a myeloablative cancer treatment such as high dose chemotherapy. Following myeloablative therapy, a cell composition of at least 25% neutrophil precursors, i.e. promyelocytes, myelocytes, and metamyelocytes, is administered to the patient. Thereafter, the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils for fighting infection. The method is used to reduce the neutropenic window between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6010697
Application Number:US1998000141441
Date Filed:27/08/1998
Date Published:04/01/2000
Assignee:Nexell Therapeutics, Inc., Irvine, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/4/2020